Stocks›Healthcare

Evonile Pharma Limited

EVONILE · BSE · Healthcare · As of 8 Nov 2026

₹1,819.00

+₹60.60 (+3.45%)(1D)

₹750.0052 Week Range₹2,588.80

Market Cap

₹3,670 Cr

P/E (Sector)

48.2 (32.3)

P/B Ratio

—

Dividend Yield

2.43%

ROE

-30.1%

Debt / Equity

—

Anvest Score

51/100

Valuation

0/100

Quality

16/100

Growth

83/100

Health

100/100

Momentum

87/100

Valuation
0
Quality
16
Growth
83
Health
100
Momentum
87

AI Company ProfileFiling-backed

AI Snapshot

Evonile Pharma Limited operates in Healthcare.

Healthcare

Business profile as of FY26 (ended 31 Mar 2026)

Revenue growth: -0.5%FY26 growth-2.2%3Y CAGR
EPS growth: -7.7%FY26 growth-3.4%3Y CAGR

What Looks Strong

MarketShareholder returns of +19.7% CAGR over five years.

What to Watch

RevenueRevenue contracted at a -2.2% CAGR over the 3-year period (FY23–FY26). Watch for revenue stabilization in upcoming quarters.
ValuationShare price has risen ~40% annualised over three years against ~-3% profit growth, increasing valuation sensitivity to a growth slowdown.

Loading company profile…

Fundamentals

P/E Ratio (TTM)

48.2

Sector median P/E

32.29

P/B Ratio

—

Sector median P/B

4.4

EPS (TTM)

₹37.74

Market Cap

₹3,670 Cr

Dividend Yield

2.43%

ROE

-30.15%

ROCE

8.18%

Profit Margin

23.7%

Evonile Pharma Limited FAQs

3 topics

Expand

What does the Evonile Pharma Limited (EVONILE) stock page cover?

Evonile Pharma Limited on Anvest includes delayed price context, valuation ratios, a one-year price range, and section-level research data when available.

What are the current headline metrics for EVONILE?

Evonile Pharma Limited is currently shown with a delayed price near ₹1,819, P/E 48.2, and ROE -30.15%.

Does the EVONILE page provide investment advice?

No. The EVONILE page is built for research, comparison, and planning. It does not publish buy, sell, or hold recommendations.

Keep exploring